ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
1.610
+0.190 (13.38%)
At close: Aug 21, 2026, 4:00 PM EDT
1.590
-0.020 (-1.24%)
After-hours: Aug 21, 2026, 7:41 PM EDT
ProKidney Market Cap
ProKidney has a market cap or net worth of $486.74 million as of August 21, 2026. Its market cap has decreased by -27.46% in one year.
Market Cap
486.74M
Enterprise Value
308.70M
1-Year Change
-27.46%
Ranking
Category
Stock Price
$1.61
ChartMarket Cap Chart
Since June 30, 2021, ProKidney's market cap has increased from $258.80M to $486.74M, an increase of 88.08%. That is a compound annual growth rate of 13.06%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 21, 2026 | 486.70M | -27.78% |
| Dec 31, 2025 | 673.90M | 36.72% |
| Dec 31, 2024 | 492.90M | 17.61% |
| Dec 29, 2023 | 419.10M | -73.75% |
| Dec 30, 2022 | 1.60B | 405.76% |
| Dec 31, 2021 | 315.70M | 21.99% |
| Jun 30, 2021 | 258.80M | - |
View and export this data all the way back to 2021. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Editas Medicine | 451.53M |
| Benitec Biopharma | 446.95M |
| Eupraxia Pharmaceuticals | 445.95M |
| Larimar Therapeutics | 434.23M |
| Atea Pharmaceuticals | 429.90M |
| Inhibikase Therapeutics | 427.88M |
| Compass Therapeutics | 425.01M |
| Foghorn Therapeutics | 416.29M |